Disc sets up polycythemia vera challenge but Silence maintains lead

RegulatoryapprovedMimryloNeutral

AI Analysis

Summary

Disc Medicine and Silence Therapeutics are advancing next-generation polycythemia vera therapies while competing against Takeda and Protagonist Therapeutics, whose Mimrylo recently received FDA approval.

Outcome Details

FDA approval for Mimrylo

Importance:6/10

Sentiment:

0.00

polycythemia veracompetitive landscapeFDA approvalnext-generation therapy

Related Companies

$DISC $SHWZ

Read the original article

Published by BioSpace on September 11, 2026 12:30 PM

Read Original